openPR Logo
Press release

Lawsuit filed for Investors in shares of AnaptysBio, Inc. (NASDAQ: ANAB)

03-31-2020 10:39 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Shareholders Foundation

A lawsuit was filed on behalf of investors in AnaptysBio, Inc. (NASDAQ: ANAB) shares over alleged securities laws violations.

A lawsuit was filed on behalf of investors in AnaptysBio, Inc. (NASDAQ: ANAB) shares over alleged securities laws violations.

An investor, who purchased shares of AnaptysBio, Inc. (NASDAQ: ANAB), filed a lawsuit over alleged violations of Federal Securities Laws by AnaptysBio, Inc..

Investors in shares of AnaptysBio, Inc. (NASDAQ: ANAB) have certain options and for certain investors are short and strict deadlines running. Deadline: May 25, 2020. NASDAQ: ANAB investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

San Diego, CA based AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing antibody product candidates focused on unmet medical needs in inflammation. AnaptysBio, Inc's lead drug asset was etokimab (formerly ANB020), a drug intended for the treatment of various inflammatory diseases. in 2018 to $97.33 million in 2019.

On March 26, 2018, an analyst from RBC Capital Markets issued a report that questioned the veracity of data from AnaptysBio's interim analysis of its Phase 2a clinical trial for etokimab in adult patients with peanut allergies that the Company had reported earlier that day. In particular, the RBC report revealed that the response rate for etokimab in the full trial population "does not appear to be meaningfully differentiated" relative to a placebo. Less than five months later, in August 2018, the Company abandoned its clinical pursuit of etokimab as a treatment for peanut allergies.

On June 21, 2019, an analyst from Credit Suisse issued a report questioning the reliability of the Company's Phase 2a atopic dermatitis trial data. Specifically, the Credit Suisse report questioned patients' use of topical corticosteroids to supplement treatment of their symptoms as a rescue therapy during the study and criticized the Company's failure to provide details on the timing of rescue therapy use or whether the subjects that utilized rescue therapy were classified as responders. As a result of the Company's misleading atopic dermatitis trial data, Credit Suisse was "now less certain about etokimab's efficacy profile, particularly in atopic dermatitis."

Then, on November 8, 2019, the Company announced "very disappoint[ing]" data from its ATLAS trial, a Phase 2b multi-dose study which evaluated the efficacy of etokimab in approximately 300 patients with moderate-to-severe atopic dermatitis. Specifically, AnaptysBio disclosed that each of the etokimab dosing arms "failed to meet the primary endpoint of the trial" by not demonstrating statistically greater efficacy relative to a placebo. As a result of these disclosures, the price of AnaptysBio common stock declined precipitously.

The plaintiff claims that between October 10, 2017 and November 7, 2019, the defendants made false and misleading statements regarding the purported efficacy of etokimab, touting data from the Company's Phase 2a trial in peanut allergies as showing a "remarkable efficacy result" and describing the drug as having a "pretty profound efficacy" in its treatment of patients with atopic dermatitis based on AnaptysBio's Phase 2a trial data for that indication, that in truth, the Defendants provided misleading clinical trial data which failed to disclose key information and used questionable analysis, making the trial results regarding etokimab's efficacy and its prospects appear far better than they were, and that as a result of Defendants' misrepresentations, shares of AnaptysBio common stock traded at artificially inflated prices between October 10, 2017 and November 7, 2019.

Those who purchased shares of AnaptysBio, Inc. (NASDAQ: ANAB) have certain options and should contact the Shareholders Foundation.

Media Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Lawsuit filed for Investors in shares of AnaptysBio, Inc. (NASDAQ: ANAB) here

News-ID: 1993643 • Views: 282

More Releases from Shareholders Foundation

Lawsuit filed for Investors in shares of Odonate Therapeutics, Inc. (NASDAQ: ODT …
An investor, who purchased shares of Odonate Therapeutics, Inc. (NASDAQ: ODT), filed a lawsuit over alleged Securities Laws violations by Odonate Therapeutics, Inc. Investors who purchased shares of Odonate Therapeutics, Inc. (NASDAQ: ODT) have certain options and for certain investors are short and strict deadlines running. Deadline: November 16, 2020. NASDAQ: ODT investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. San Diego, CA based Odonate Therapeutics,
Investigation announced for Investors in NASDAQ: PINC over possible Wrongdoing a …
An investigation on behalf of investors in shares of Premier, Inc. (NASDAQ: PINC) was announced over potential breaches of fiduciary duties by certain officers and directors at Premier, Inc. Investors who purchased shares of Premier, Inc. (NASDAQ: PINC) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm concerns whether certain Premier, Inc. directors breached their fiduciary duties and
Deadline on October 9th coming up in Lawsuit for Investors in shares of MEI Phar …
A deadline is coming up on October 9, 2020 in the lawsuit filed for certain investors of MEI Pharma, Inc. (NASDAQ: MEIP) over alleged securities laws violations by MEI Pharma, Inc. Investors who purchased shares of MEI Pharma, Inc. (NASDAQ: MEIP) have certain options and there are strict and short deadlines running. Deadline: October 9, 2020. NASDAQ: MEIP stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 -
Investigation announced for Long-Term Investors in shares of Casper Sleep Inc. ( …
An investigation on behalf of current long-term investors in shares of Casper Sleep Inc. (NYSE: CSPR) concerning potential breaches of fiduciary duties by certain directors and officers of Casper Sleep Inc. was announced. Investors who are current long term investors in Casper Sleep Inc. (NYSE: CSPR) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for

All 5 Releases


More Releases for AnaptysBio

Investigation announced for Investors in AnaptysBio, Inc. (NASDAQ: ANAB) over po …
An investigation on behalf of investors in shares of AnaptysBio, Inc. (NASDAQ: ANAB) was announced over potential breaches of fiduciary duties by certain officers and directors at AnaptysBio, Inc. Investors who purchased shares of AnaptysBio, Inc. (NASDAQ: ANAB) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm concerns whether certain AnaptysBio, Inc. directors breached their fiduciary duties and
AnaptysBio, Inc. (NASDAQ: ANAB) Long Term Investor Alert: Investigation of poten …
An investigation on behalf of current long-term investors in shares of AnaptysBio, Inc. (NASDAQ: ANAB) concerning potential breaches of fiduciary duties by certain directors and officers of AnaptysBio, Inc was announced. Investors who are current long term investors in AnaptysBio, Inc. (NASDAQ: ANAB) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term
Deadline on May 25th coming up in Lawsuit filed for Investors in shares of Anapt …
A deadline is coming up on May 25, 2020 in the lawsuit filed for certain investors of AnaptysBio, Inc. (NASDAQ: ANAB) over alleged securities laws violations by AnaptysBio, Inc. Investors who purchased shares of AnaptysBio, Inc. (NASDAQ: ANAB) have certain options and there are strict and short deadlines running. Deadline: May 25, 2020. NASDAQ: ANAB stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. According to the
Allergy Therapeutics - Pipeline Analysis 2018 | AnaptysBio, HAL Allergy Group, A …
Allergy is an immune system response, that can range from mild to severe life-threatening reactions. The substances that can cause an allergy are known as allergens. Some common allergens include pollen, dust, insect stings, medications, mold spores, latex, and animal dander. Download the sample report @ https://www.pharmaproff.com/request-sample/1045 Allergy triggers the release of inflammatory mediators such as interleukins, serotonin, cytokines, and prostaglandins, which can produce several systemic physiological reactions like mucous secretion and
Peanut Allergy Therapeutics Pipeline - Key Players Analysis Aimmune Therapeutics …
Peanut allergy is one of the most common type of allergies caused by a legume, known as peanut. Peanut is an annual herbaceous plant that belongs to the family of legumes. Other examples of legumes that can cause the disease include lentils, peas, and soybeans. Peanut allergy can be unpredictable and life-threatening and can bring the body into shock (anaphylaxis). The study analyzed that peanut allergy therapeutics pipeline comprises approximately
Dermatology Drugs Market By Growth Factors and Key Players: Allergan Plc, Valean …
The Future of Dermatology Drugs Market: Novel Treatments and Increased Diagnosis in Psoriasis and Atopic Dermatitis Drives Market Growth “Dermatology Drugs Market by Therapeutic Area Segments (Atopic Dermatitis, Psoriasis, Acne, Rosacea), Acne Drug Types (Doxycycline, Absorica, Clindamycin, Myorisan, Aczone, Epiduo) Marketed Therapies (Biologics, Oral Drugs, Topical Drugs), by Approves Treatments (Etanercept (Enbrel), Infliximab (Remicade), Adalimumab (Humira), Ustekinumab (Stelara), Secukinumab (Cosentyx), Ixekizumab (Taltz), Golimumab (Simponi), Brodalumab (Siliq), Guselkamab (Tremfya) and Others) and